A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis.

Caspofungin is a new broad-spectrum antifungal drug. A multicenter, double-blind, randomized trial was conducted to assess the efficacy, safety, and tolerability of caspofungin relative to amphotericin B in adults with endoscopically documented symptomatic Candida esophagitis. By use of a modified intent-to-treat analysis, endoscopically verified clinical success was achieved in 74% (95% confidence interval [CI], 59%-86%) and 89% (95% CI, 72%-98%) of patients receiving caspofungin at 50 and 70 mg/day, respectively, and in 63% (95% CI, 49%-76%) of patients given amphotericin B at 0.5 mg/kg/day. Therapy was stopped because of drug-related adverse events in 24% of patients in the amphotericin B group and 4% and 7%, respectively, for the caspofungin groups. This report provides the first demonstration of clinical utility for an echinocandin compound. Caspofungin appeared in this study to be as effective as and better tolerated than amphotericin B for the treatment of esophageal candidiasis.

[1]  C. Weijer,et al.  Reporting the study populations of clinical trials. Clear transmission or static on the line? , 2000, Journal of clinical epidemiology.

[2]  C. González,et al.  Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients. , 2000 .

[3]  S J Pocock,et al.  Randomized trials or observational tribulations? , 2000, The New England journal of medicine.

[4]  S. Piscitelli,et al.  Correlation between In Vitro and In Vivo Antifungal Activities in Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis , 2000, Journal of Clinical Microbiology.

[5]  M. Lindegren,et al.  Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Sobel,et al.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  F. Mühlschlegel,et al.  The Role of Candida dubliniensis in Oral Candidiasis in Human Immunodeficiency Virus-Infected Individuals , 2000, Critical reviews in microbiology.

[8]  Daniel S. Miller,et al.  Trends in self-reported use of mammograms (1989-1997) and Papanicolaou tests (1991-1997)--Behavioral Risk Factor Surveillance System. , 1999, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[9]  V. Andriole,et al.  The 1998 Garrod lecture. Current and future antifungal therapy: new targets for antifungal agents. , 1999, The Journal of antimicrobial chemotherapy.

[10]  M. Rinaldi,et al.  In Vitro Activity of the New Echinocandin Antifungal, MK-0991, against Common and Uncommon Clinical Isolates of Candida Species , 1999, European Journal of Clinical Microbiology and Infectious Diseases.

[11]  D. Soll,et al.  In Vitro Susceptibilities of Candida dubliniensisIsolates Tested against the New Triazole and Echinocandin Antifungal Agents , 1999, Journal of Clinical Microbiology.

[12]  Robin Patel,et al.  Antifungal agents. Part I. Amphotericin B preparations and flucytosine. , 1998, Mayo Clinic proceedings.

[13]  E. Anaissie,et al.  Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  S. Redding,et al.  Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  G. Noskin,et al.  Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  E. Anaissie,et al.  Optimizing the Correlation between Results of Testing In Vitro and Therapeutic Outcome In Vivo for Fluconazole by Testing Critical Isolates in a Murine Model of Invasive Candidiasis , 1998, Antimicrobial Agents and Chemotherapy.

[17]  J. Rex,et al.  Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  J. Galgiani,et al.  Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans , 1997, Antimicrobial agents and chemotherapy.

[19]  J. Graybill,et al.  Treatment of murine Candida krusei or Candida glabrata infection with L-743,872 , 1997, Antimicrobial agents and chemotherapy.

[20]  J. Sobel,et al.  In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species , 1997, Antimicrobial agents and chemotherapy.

[21]  M. Henman,et al.  Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro , 1997, Antimicrobial agents and chemotherapy.

[22]  J. Martínez-Suárez,et al.  Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  M. Ghannoum,et al.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  S. Redding,et al.  Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. , 1996, The Journal of infectious diseases.

[25]  J. Martínez-Suárez,et al.  In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates , 1996, Antimicrobial agents and chemotherapy.

[26]  T J Walsh,et al.  Antifungal agents: chemotherapeutic targets and immunologic strategies , 1996, Antimicrobial agents and chemotherapy.

[27]  J. Martínez-Suárez,et al.  Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain , 1995, Antimicrobial agents and chemotherapy.

[28]  T. Flanigan,et al.  Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  C. Kauffman,et al.  Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. , 1994, The American journal of medicine.

[30]  M. Trautmann,et al.  Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection , 1994, Journal of clinical microbiology.

[31]  C. Viscoli,et al.  Developing improved observational methods for evaluating therapeutic effectiveness. , 1990, The American journal of medicine.

[32]  M. Masiá Canuto,et al.  Determinants for the Development of Oropharyngeal Colonization or Infection by Fluconazole-Resistant Candida Strains in HIV-Infected Patients , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[33]  A. Oliver,et al.  Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: antibiotic use as risk factor for colonization and infection. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Centers for Disease Control and Prevention. , 1999, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[35]  M. Rinaldi,et al.  In Vitro Activity of the New Echinocandin Antifungal, MK-0991, against Common and Uncommon Clinical Isolates of , 1999 .

[36]  D. Landman,et al.  Failure of all antifungal therapy for infection due to Candida albicans: a new AIDS-related problem? , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.